RANDOMIZED COMPARISON OF ETOPOSIDE-CISPLATIN VS ETOPOSIDE-CARBOPLATIN AND IRRADIATION IN SMALL-CELL LUNG-CANCER - A HELLENIC COOPERATIVE ONCOLOGY GROUP-STUDY

被引:190
作者
SKARLOS, DV
SAMANTAS, E
KOSMIDIS, P
FOUNTZILAS, G
ANGELIDOU, M
PALAMIDAS, P
MYLONAKIS, N
PROVATA, A
PAPADAKIS, E
KLOUVAS, G
THEOCHARIS, D
PANOUSAKI, E
BOLETI, E
SPHAKIANOUDIS, G
PAVLIDIS, N
机构
[1] SISMANOGLIO GEN HOSP,ATHENS,GREECE
[2] METAXAS CANC CTR,PIRAEUS,GREECE
[3] UNIV HOSP THESSALONIKI,AHEPA,THESSALONIKI,GREECE
[4] AMELIA FLEMING GEN HOSP,ATHENS,GREECE
[5] HOSP CHEST DIS SOTIRIA,ATHENS,GREECE
[6] ARMY FUND HOSP,NIMTS,ATHENS,GREECE
[7] UNIV IOANNINA,SCH MED,DEPT ONCOL,IOANNINA,GREECE
关键词
SMALL-CELL LUNG CANCER (SCLC); CISPLATIN; ETOPOSIDE; CARBOPLATIN;
D O I
10.1093/oxfordjournals.annonc.a058931
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To compare the efficacy and toxicity of etoposide and cisplatin (EP) with etoposide and carboplatin (EC) in combination with irradiation in small-cell lung cancer (SCLC). Methods: Previously untreated patients (pts) with SCLC and measurable or evaluable disease were randomized to receive either cisplatin 50 mg/m2 on days 1-2 or carboplatin 300 mg/m2 on day 1, both combined with etoposide 300 mg/m2 on days 1-3 every 21 days for 6 treatment cycles. The vast majority of responding limited disease (LD) pts and complete responders (CR) with extensive disease (ED), also received thoracic irradiation (TI) and prophylactic cranial irradiation (PCI) concurrently with the third cycle. Results: Of the 147 patients registered, 143 were eligible; median performance status (PS, WHO) was 1, and tumour stage was LD in 41 pts of each treatment group. The mean delay between cycles was 8 days in the EP group and 9 in the EC group increasing in both arms with the number of treatment courses. The drug dose administered per unit time as a proportion of the protocol dose was 74% and 80% for the two groups respectively. Leukopenia, neutropenic infections, nausea, vomiting, neurotoxicity and hyperergic reactions were more frequent and/or severe in the EP group. The CR rates were 57% and 58% for EP and EC respectively. Median survival for all pts was 12.5 and 11.8 months, respectively. Conclusion: Both treatments proved to be effective, with no differences in response and survival between the two treatment arms. The EC regimen was associated with significantly less toxicity.
引用
收藏
页码:601 / 607
页数:7
相关论文
共 55 条
[1]   DETERMINANTS OF IMPROVED OUTCOME IN SMALL-CELL LUNG-CANCER - AN ANALYSIS OF THE 2,580-PATIENT SOUTHWEST ONCOLOGY GROUP DATA-BASE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) :1563-1574
[2]   CARBOPLATIN (CBDCA, JM-8) AND VP-16-213 IN PREVIOUSLY UNTREATED PATIENTS WITH SMALL-CELL LUNG-CANCER [J].
BISHOP, JF ;
RAGHAVAN, D ;
STUARTHARRIS, R ;
MORSTYN, G ;
ARONEY, R ;
KEFFORD, R ;
YUEN, K ;
LEE, J ;
GIANOUTSOS, P ;
OLVER, IN ;
ZALCBERG, J ;
BALL, D ;
BULL, C ;
FOX, R .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (10) :1574-1578
[3]  
BONI C, 1989, CANCER, V63, P638, DOI 10.1002/1097-0142(19890215)63:4<638::AID-CNCR2820630406>3.0.CO
[4]  
2-8
[5]   TENIPOSIDE (VM-26), AN OVERLOOKED HIGHLY-ACTIVE AGENT IN SMALL-CELL LUNG-CANCER - RESULTS OF A PHASE-II TRIAL IN UNTREATED PATIENTS [J].
BORK, E ;
HANSEN, M ;
DOMBERNOWSKY, P ;
HANSEN, SW ;
PEDERSEN, AG ;
HANSEN, HH .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (04) :524-527
[6]  
Bunn P A Jr, 1992, Semin Oncol, V19, P1
[7]  
BUNN PA, 1986, SEMIN ONCOL, V13, P45
[8]  
BUNN PA, 1987, ANN INTERN MED, V106, P55
[9]   EARLY CLINICAL-STUDIES WITH CIS-DIAMMINE-1,1-CYCLOBUTANE DICARBOXYLATE PLATINUM-II [J].
CALVERT, AH ;
HARLAND, SJ ;
NEWELL, DR ;
SIDDIK, ZH ;
JONES, AC ;
MCELWAIN, TJ ;
RAJU, S ;
WILTSHAW, E ;
SMITH, IE ;
BAKER, JM ;
PECKHAM, MJ ;
HARRAP, KR .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 9 (03) :140-147
[10]  
DIXON WJ, 1990, BMDP STATISTICAL SOF, P135